{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:03:02Z","timestamp":1792684982906,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"am","delay-in-days":382,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["W81XMH2110665"],"award-info":[{"award-number":["W81XMH2110665"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-16-1-0570"],"award-info":[{"award-number":["W81XWH-16-1-0570"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pancreatology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.pan.2025.01.004","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T07:40:54Z","timestamp":1736754054000},"page":"214-220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety, tolerability and therapeutic efficacy of anti-inflammatory drug pirfenidone in acute pancreatitis patients: Protocol for a randomized pilot clinical trial"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1719-2451","authenticated-orcid":false,"given":"Ejas P.","family":"Bava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1886-685X","authenticated-orcid":false,"given":"Tejeshwar","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Al-Obaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dureti","family":"Doto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santhi Swaroop","family":"Vege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Dudeja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pan.2025.01.004_bib1","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1053\/j.gastro.2015.07.066","article-title":"Frequency of progression from acute to chronic pancreatitis and risk factors: a meta-analysis","volume":"149","author":"Sankaran","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pan.2025.01.004_bib2","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1172\/jci.insight.141108","article-title":"Pirfenidone increases IL-10 and improves acute pancreatitis in multiple clinically relevant murine models","volume":"7","author":"Palathingal Bava","year":"2022","journal-title":"JCI Insight"},{"issue":"20211231","key":"10.1016\/j.pan.2025.01.004_bib3","article-title":"Efficacy and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis patients: a systematic review and meta-analysis of randomised controlled trials","volume":"11","author":"Wu","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.pan.2025.01.004_bib4","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1053\/j.gastro.2015.04.019","article-title":"Pentoxifylline treatment in severe acute pancreatitis: a pilot, double-blind, placebo-controlled, randomized trial","volume":"149","author":"Vege","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pan.2025.01.004_bib5","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A\u00a0phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pan.2025.01.004_bib6","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1136\/gut.48.1.62","article-title":"Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis","volume":"48","author":"Johnson","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.pan.2025.01.004_bib7","doi-asserted-by":"crossref","first-page":"4735","DOI":"10.3748\/wjg.14.4735","article-title":"Therapy for acute pancreatitis with platelet-activating factor receptor antagonists","volume":"14","author":"Chen","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.pan.2025.01.004_bib8","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1006\/jsre.2001.6206","article-title":"Platelet activating factor antagonism reduces the systemic inflammatory response in a murine model of acute pancreatitis","volume":"99","author":"Lane","year":"2001","journal-title":"J\u00a0Surg Res"},{"key":"10.1016\/j.pan.2025.01.004_bib9","doi-asserted-by":"crossref","first-page":"473","DOI":"10.14309\/ajg.0000000000000529","article-title":"Prevention of severe acute pancreatitis with cyclooxygenase-2 inhibitors: a randomized controlled clinical trial","volume":"115","author":"Huang","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.pan.2025.01.004_bib10","first-page":"CD011384","article-title":"Pharmacological interventions for acute pancreatitis","volume":"4","author":"Moggia","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pan.2025.01.004_bib11","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3121\/cmr.2021.1663","article-title":"Ketorolac and predicted severe acute pancreatitis: a randomized, controlled clinical trial","volume":"20","author":"Shariatpanahi","year":"2022","journal-title":"Clin Med Res"},{"key":"10.1016\/j.pan.2025.01.004_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165244","article-title":"Analysis of research activity in gastroenterology: pancreatitis is in real danger","volume":"11","author":"Szentesi","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.pan.2025.01.004_bib13","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/j.pan.2020.09.023","article-title":"A\u00a0single center randomized double blind controlled trial of pentoxifylline in acute pancreatitis: challenges and opportunities","volume":"20","author":"Vege","year":"2020","journal-title":"Pancreatology : official journal of the International Association of Pancreatology (IAP) [et\u00a0al]"},{"key":"10.1016\/j.pan.2025.01.004_bib14","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1053\/j.gastro.2018.01.031","article-title":"Initial medical treatment of acute pancreatitis: American gastroenterological association institute technical review","volume":"154","author":"Vege","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pan.2025.01.004_bib15","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/SLA.0000000000002766","article-title":"Determinants of severity in acute pancreatitis: a nation-wide multicenter prospective cohort study","volume":"270","author":"Sternby","year":"2019","journal-title":"Ann Surg"},{"key":"10.1016\/j.pan.2025.01.004_bib16","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/ajg.2017.114","article-title":"Dynamic measurement of disease activity in acute pancreatitis: the pancreatitis activity scoring system","volume":"112","author":"Wu","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.pan.2025.01.004_bib17","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1001\/jama.1983.03330480037027","article-title":"Functional health status levels of primary care patients","volume":"249","author":"Nelson","year":"1983","journal-title":"JAMA"},{"key":"10.1016\/j.pan.2025.01.004_bib18","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.2196\/jmir.7789","article-title":"Patient-reported measures for person-centered coordinated care: a comparative domain map and web-based compendium for supporting policy development and implementation","volume":"20","author":"Lloyd","year":"2018","journal-title":"J\u00a0Med Internet Res"},{"issue":"2010\/01\/20","key":"10.1016\/j.pan.2025.01.004_bib19","doi-asserted-by":"crossref","first-page":"c186","DOI":"10.1136\/bmj.c186","article-title":"The routine use of patient reported outcome measures in healthcare settings","volume":"340","author":"Dawson","year":"2010","journal-title":"Br Med J"},{"issue":"i-iv","key":"10.1016\/j.pan.2025.01.004_bib20","first-page":"1","article-title":"Evaluating patient-based outcome measures for use in clinical trials","volume":"2","author":"Fitzpatrick","year":"1998","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.pan.2025.01.004_bib21","article-title":"Patient reported outcome measures in practice","volume":"350","author":"Nelson","year":"2015","journal-title":"Br Med J"},{"key":"10.1016\/j.pan.2025.01.004_bib22","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/gutjnl-2020-320729","article-title":"Design and validation of a patient-reported outcome measure scale in acute pancreatitis: the PAN-PROMISE study","volume":"70","author":"de-Madaria","year":"2021","journal-title":"Gut"}],"container-title":["Pancreatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1424390325000043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1424390325000043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T07:07:42Z","timestamp":1743059262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1424390325000043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1424390325000043"],"URL":"https:\/\/doi.org\/10.1016\/j.pan.2025.01.004","relation":{},"ISSN":["1424-3903"],"issn-type":[{"value":"1424-3903","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, tolerability and therapeutic efficacy of anti-inflammatory drug pirfenidone in acute pancreatitis patients: Protocol for a randomized pilot clinical trial","name":"articletitle","label":"Article Title"},{"value":"Pancreatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pan.2025.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 IAP and EPC. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}